Table of Contents

company-logo

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Ensysce Biosciences Dividend Announcement

• Ensysce Biosciences does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Ensysce Biosciences dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Ensysce Biosciences Dividend History

Ensysce Biosciences Dividend Yield

Ensysce Biosciences current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Ensysce Biosciences stock? Use our calculator to estimate your expected dividend yield:

Ensysce Biosciences Financial Ratios

P/E ratio-0.60
PEG ratio-0.01
P/B ratio0.69
ROE-268.39%
Payout ratio-0.06%
Current ratio3.24
Quick ratio3.24
Cash Ratio1.48

Ensysce Biosciences Dividend FAQ

Does Ensysce Biosciences stock pay dividends?
Ensysce Biosciences does not currently pay dividends to its shareholders.
Has Ensysce Biosciences ever paid a dividend?
No, Ensysce Biosciences has no a history of paying dividends to its shareholders. Ensysce Biosciences is not known for its dividend payments.
Why doesn't Ensysce Biosciences pay dividends?
There are several potential reasons why Ensysce Biosciences would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Ensysce Biosciences ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Ensysce Biosciences has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Ensysce Biosciences a dividend aristocrat?
Ensysce Biosciences is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Ensysce Biosciences a dividend king?
Ensysce Biosciences is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Ensysce Biosciences a dividend stock?
No, Ensysce Biosciences is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Ensysce Biosciences stocks?
To buy Ensysce Biosciences you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Ensysce Biosciences stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.